News
Important Only
Avidity Biosciences Receives FDA Breakthrough Therapy Designation For Duchenne Muscular Dystrophy Treatment
July 23 (Reuters) - Avidity Biosciences Inc RNA.O:AVIDITY BIOSCIENCES RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DELPACIBART ZOTADIRSEN (DEL-ZOTA) FOR THE TREATMENT OF DMD IN PEOPLE WITH MUTATIONS AMENABLE TO EXON 44 SKIPPINGAVIDITY BIOSCIENCES INC - ON TRACK FOR BLA SUBMISSION FOR DEL-ZOTA B...Reuters
Wed, Jul 23
BASF And Altagas Sign Long-Term Butane Supply Agreement
July 23 (Reuters) - BASF BASFn.DE:BASF AND ALTAGAS SIGN LONG-TERM BUTANE SUPPLY AGREEMENTSIGNED A LONG-TERM COMMERCIAL AGREEMENT FOR SUPPLY OF BUTANE VIA ALTAGAS AND ROYAL VOPAK'S RIDLEY ISLAND ENERGY EXPORT FACILITY ("REEF") COMMENCING IN 2027REEF IS EXPECTED TO BE COMPLETED BY 2026 YEA...Reuters
Wed, Jul 23
Thermo Fisher Scientific’s CFO, Stephen Williamson, To Retire In Early 2026
July 23 (Reuters) - Thermo Fisher Scientific Inc TMO.N:THERMO FISHER SCIENTIFIC’S CHIEF FINANCIAL OFFICER, STEPHEN WILLIAMSON, TO RETIRE IN EARLY 2026THERMO FISHER SCIENTIFIC’S CHIEF FINANCIAL OFFICER, STEPHEN WILLIAMSON, TO RETIRE IN EARLY 2026THERMO FISHER SCIENTIFIC INC: JIM MEYER TO BECOME CHIEF...Reuters
Wed, Jul 23
Russian Tu-95MS nuclear-capable strategic bombers complete patrol over Bering Sea, IFX reports
MOSCOW, July 23 (Reuters) - Russian Tu-95MS nuclear-capable strategic bombers have completed a routine patrol flight over international waters in the Bering Sea, the Interfax news agency reported on Wednesday, citing the Russian Defence Ministry.Foreign fighter jets were scrambled to track the fligh...Reuters
Wed, Jul 23
Scotiabank Comments On Expected Contribution From KeyCorp's Second Quarter Earnings
July 23 (Reuters) - Bank of Nova Scotia BNS.TO:SCOTIABANK COMMENTS ON EXPECTED CONTRIBUTION FROM KEYCORP'S SECOND QUARTER EARNINGSSCOTIABANK- EXPECTS CAD $61 MILLION CONTRIBUTION TO NET INCOME FROM KEYCORP OWNERSHIP INTEREST IN Q3Reuters
Wed, Jul 23
India accuses Walmart's Myntra of breaching foreign investment rules
Myntra one of India's top fashion e-commerce retailersInvestigation follows antitrust scrutiny of Amazon, FlipkartMyntra says no complaint copy received, pledges cooperationIndia's e-commerce market seen reaching $345 billion by 2030By Munsif Vengattil and Aditya Kalra BENGALURU, July 23 ...Reuters
Wed, Jul 23
Turkey nears Eurofighter jet purchase after UK, German agreements
Germany approves delivery of 40 Eurofighter Typhoon jets to TurkeyUK, Turkey deal to allow Ankara to operate the jetsTurkey in talks with US for 40 F-16s amid regional tensionsBy Ezgi Erkoyun ISTANBUL, July 23 (Reuters) - Turkey reached deals with NATO allies Britain and Germany on Wednesday that...Reuters
Wed, Jul 23
Unipol Tells Market Regulator Consob Its Higher Stake In Bper Banca Is Temporary, Will Return Below 20% After Bper Bid On Pop Sondrio Is Concluded
Bper Banca SpA EMII.MI:JPMORGAN CUT STAKE IN BPER BANCA TO 0.321% FROM 3.093% AS OF JULY 16 - FILINGUNIPOL ASSICURAZIONI RAISED STAKE IN BPER BANCA TO 22.772% FROM 19.774% AS OF JULY 18 - FILINGUNIPOL TELLS MARKET REGULATOR CONSOB ITS HIGHER STAKE IN BPER BANCA IS TEMPORARY, WILL RETURN BELOW 20% AF...Reuters
Wed, Jul 23
European Commission Approves J&J's Imbruvica As First Targeted Therapy For Some Patients With Untreated Mantle Cell Lymphoma
July 23 (Reuters) - Johnson & Johnson JNJ.N:J&J: EC APPROVES IMBRUVICA AS FIRST TARGETED THERAPY FOR SOME PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMASource text: [ID:]Reuters
Wed, Jul 23
John Marshall's Q2 net income rises on higher loan demand
OverviewJohn Marshall Bancorp Q2 net income rises 30.7% yr/yr to $5.1 mlnDiluted EPS for Q2 increases 33.3% yr/yr, driven by loan growthNet interest income for Q2 grows 23.5% yr/yr, reflecting margin expansionOutlookCompany anticipates continued growth in loan commitmentsCompany sees potential for n...Reuters
Wed, Jul 23
European Commission Approves J&J's Darzalex As First Treatment For Patients With High-Risk Smouldering Multiple Myeloma
July 23 (Reuters) - Johnson & Johnson JNJ.N:EUROPEAN COMMISSION APPROVES DARZALEX® (DARATUMUMAB) AS THE FIRST LICENSED TREATMENT FOR PATIENTS WITH HIGH-RISK SMOULDERING MULTIPLE MYELOMASource text: [ID:]Reuters
Wed, Jul 23
